CLLS

Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis SA (CLLS) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -3.9
Rev Growth YoY -37.3%
Gross Margin N/M
Price Return 3M -25.1%
Price Return 12M -6.1%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 3.7
ROE -76.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D+ (1.8) C+ (2.8) C (2.4) C- (1.9) C (2.3)
2026-08-04 C+ (2.7) D+ (1.8) C+ (2.8) C (2.4) C- (1.9) C (2.3)
2026-08-03 C+ (2.7) C (2.2) C+ (2.6) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C (2.2) C+ (2.6) C (2.4) C- (1.9) C (2.4)